Demographics |
Age: median (range) |
64 (47–84) |
63 (47–81) |
62 (47–84) |
.86 |
Age 65 years: # (%) |
23 (43) |
13 (45) |
10 (42) |
.82 |
Male: # (%) |
29 (55) |
19 (66) |
10 (42) |
.08 |
Caucasian: # (%) |
45 (85) |
26 (90) |
19 (79) |
.29 |
ECOG performance score = 0: # (%) |
33 (62) |
19 (66) |
14 (58) |
.59 |
Baseline laboratory data |
Total lymphocyte count: median (range) |
1945 (580–4200) |
2030 (580–3280) |
1599 (870–4200) |
.57 |
Lymphocyte ≥ 1,000: # (%) |
48 (91) |
26 (90) |
22 (92) |
.80 |
AST: median (range) |
28 (12–70) |
28 (12–53) |
28 (12–70) |
.42 |
BUN: median (range) |
12 (5–34) |
14 (5–34) |
12 (5–27) |
.31 |
CA19-9: median (range) |
41 (0.1–400) |
29 (0.1–440) |
60 (4.9–203) |
.39 |
Albumin: median (range) |
4 (2.8–5.1) |
4.1 (2.8–4.7) |
3.9 (3–5.1) |
.56 |
Alk phos: median (range) |
113 (54–493) |
103 (54–493) |
129 (59–492) |
.18 |
Tumor staging data |
Tumor location: No. head (%) |
43 (81) |
22 (76) |
21 (88) |
.54 |
Tumor size: median centimeters (range) |
3 (1.4–9.5) |
3.5 (1.4–9.5) |
3 (1.5–6) |
.69 |
Poorly differentiated pathology: #(%) |
23 (43) |
11 (40) |
12 (50) |
.38 |
Positive margins: # (%) |
25 (47) |
13 (45) |
12 (50) |
.71 |
Positive nodes: # (%) |
48 (92) |
27 (93) |
21 (91) |
.81 |
Whipple procedure: # (%) |
44 (83) |
23 (79) |
21 (88) |
0.43 |
Postoperative treatment data |
Radiation dose: median cGy (range) |
5040 (2700–5760) |
5040 (2750–5580) |
5000 (2700–5760) |
.25 |
5-fU based chemotherapy: # % |
31 (59) |
16 (55) |
15 (63) |
.59 |